Inovio Pharmaceuticals' (INO) "Neutral" Rating Reaffirmed at HC Wainwright

Key Points

• HC Wainwright has reiterated a "neutral" rating for Inovio Pharmaceuticals (INO) with a price target of $3.00, indicating a potential upside of 76.47% from the current stock price.
• Multiple analysts have varying views on INO, with ratings ranging from "hold" to "overweight", and an average target price of $8.80.
• Inovio recently reported an EPS of ($0.61), surpassing consensus estimates, and analysts expect the company to post -4.23 earnings per share for the current year.

HC Wainwright reiterated their neutral rating on shares of Inovio Pharmaceuticals (NASDAQ:INO - Free Report) in a research report released on Thursday morning,Benzinga reports. HC Wainwright currently has a $3.00 price objective on the biopharmaceutical company's stock.

Several other equities analysts have also recently issued reports on INO. Royal Bank Of Canada reissued a "sector perform" rating and issued a $5.00 price objective on shares of Inovio Pharmaceuticals in a report on Wednesday, May 14th. Oppenheimer cut their price target on Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating for the company in a research note on Wednesday, May 14th. Piper Sandler started coverage on Inovio Pharmaceuticals in a research note on Wednesday, July 9th. They issued an "overweight" rating and a $5.00 price target for the company. Finally, Wall Street Zen upgraded Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday, June 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Inovio Pharmaceuticals has a consensus rating of "Hold" and an average price target of $8.80.

Inovio Pharmaceuticals Stock Performance

INO traded up $0.24 during trading on Thursday, hitting $1.86. 11,659,109 shares of the stock were exchanged, compared to its average volume of 1,358,878. The firm has a 50 day simple moving average of $1.67 and a 200 day simple moving average of $1.83. The firm has a market cap of $68.21 million, a price-to-earnings ratio of -0.71 and a beta of 1.38. Inovio Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $8.01.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.02. As a group, equities analysts anticipate that Inovio Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of INO. Nomura Holdings Inc. purchased a new position in shares of Inovio Pharmaceuticals during the first quarter worth about $28,000. Alpine Global Management LLC purchased a new position in shares of Inovio Pharmaceuticals during the fourth quarter worth about $31,000. Freedom Investment Management Inc. purchased a new position in shares of Inovio Pharmaceuticals during the first quarter worth about $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Inovio Pharmaceuticals by 39.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 5,894 shares during the last quarter. Finally, Catalyst Funds Management Pty Ltd purchased a new position in shares of Inovio Pharmaceuticals during the second quarter worth about $35,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.